First Patient enrolled in Phase III trial of AKVANO® Calcipotriol Spray, a new high- comfort, high-control anti-psoriasis spray
Psoriasis is a chronic disease affecting 2-4% of the world’s population. A new anti-psoriasis spray now in phase III trial offers more comfort to patients, and improves dose control. The first patient has now entered the trial.
Lipidor’s Calcipotriol Spray is being evaluated over 8 weeks of treatment in a randomized multicentre placebo-controlled phase III trial. The primary endpoint is to assess the therapeutic equivalence of the Calcipotriol Spray with comparator product. In total 266 patients with mild to moderate psoriasis will be enrolled in the trial.
“We are pleased to have enrolled the first patient in this phase III trial, which has been designed to support registration in Europe, North America and other major markets.”, says Lipidor CEO Ola Holmlund. “We believe that Calcipotriol Spray formulated using our patented AKVANO® technology will offer a great advantage compared to...
CPhI India 2018
04/12 - 06/12
Swiss Venture Club Prix 2015
Cerbios has been awarded second place at the bi-annual Swiss Venture Club Prix.
“This is an important recognition for Cerbios, the founders that created it in the late 70’s, the management and all employees that made this possible” confirms Gabriel Haering, Cerbios’ CEO.
“Being one of the six finalists chosen among 50 companies representing different industrial branches in Ticino was already a great achievement. Reaching the second place among the six finalist is splendid!”
The main criteria for the choice of finalists and winners were the following:
- Innovation as key company value
- Regional presence and impact at different levels
- An excellent track record
- Leadership in the reference market
- Operational sustainability
This award is not only a recognition for Cerbios’ strategy and approach but also a commitment towards the future in order to maintain the high standard achieved.